
Incyte (INCY) Stock Forecast & Price Target
Incyte (INCY) Analyst Ratings
Bulls say
Incyte's recent financial performance reflects strong revenue growth driven primarily by robust demand for Jakafi, which experienced a 10% year-over-year increase in paid demand across all indications. The firm has also seen significant advancement in its dermatology sector, with Opzelura achieving $188 million in revenue, surpassing expectations and benefiting from increased patient demand for atopic dermatitis and vitiligo treatments. Furthermore, Incyte has raised its full-year 2025 guidance to $4.23 billion - $4.32 billion, bolstered by increased revenue forecasts for Jakafi and other oncology products, showcasing the company's strong market position and potential for continued growth.
Bears say
Incyte faces several significant challenges that contribute to a negative outlook on its stock. Key risks include eroding pricing power for its leading drug, Jakafi, alongside poor performance from the earlier-stage pipeline, which may lead to disappointing outcomes for ongoing clinical trials. Additionally, potential disruptions from increased competition, reimbursement challenges, and safety concerns regarding marketed products further jeopardize the company's revenue and growth prospects.
This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.
Incyte (INCY) Analyst Forecast & Price Prediction
Start investing in Incyte (INCY)
Order type
Buy in
Order amount
Est. shares
0 shares